Carbonyl reductase 1-overexpressing exosomes inhibit proliferation of ovarian cancer cells

DOI 機関リポジトリ HANDLE Web Site
  • Takabayashi-Ebina Anna
    Department of Obstetrics and Gynecology, Hirosaki University, Graduate School of Medicine
  • Yokoyama Minako
    Department of Obstetrics and Gynecology, Hirosaki University, Graduate School of Medicine
  • Horie Kayo
    Department of Bioscience and Laboratory Medicine, Hirosaki University, Graduate School of Health Sciences
  • Yokoyama Yoshihito
    Department of Obstetrics and Gynecology, Hirosaki University, Graduate School of Medicine

この論文をさがす

抄録

    We previously reported that a human carbonyl reductase 1 （CBR1） DNA-dendrimer complex could potentially be used in gene therapy for peritoneal metastasis of ovarian cancer. The aims of the current study were to make exosomes which overexpressed CBR1 and to examine the antiproliferative effect of using the CBR1- overexpressing exosomes on ovarian cancer cells. Endometrial stromal cells （fibroblasts） were transfected with CBR1 DNA by using Lipofectamine, the highest expression level of CBR1 was produced from the cells transfected under the condition of Lipofectamin 24 μl/DNA 36 μg for 48 h. Exosomes were purified from culture supernatants by exoEasy Maxi Kit. Western blot showed that CBR1 notably expressed in exosomes extracted from the stromal cells transfected with CBR1 DNA. Proliferation of ovarian cancer cell line was significantly inhibited by adding CBR1- overexpressing exosomes compared to proliferation of those cells in which exosomes without CBR1 DNA were added. We obtained the evidence that CBR1-overexpressing exosomes could function in carrying CBR1 DNA into ovarian cancer cells. Results suggested that exosomes are a useful tool of gene delivery and that a gene therapy of combining CBR1 DNA and exosomes may be promoted in the treatment of advanced and recurrent ovarian cancers with peritoneal dissemination.

収録刊行物

  • 弘前医学

    弘前医学 71 (2-4), 120-130, 2021

    弘前大学大学院医学研究科・弘前医学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ